● the costs of outside consultants, including their fees, stock-based compensation and related travel expenses; ● the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; ● salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; and ● facility-related expenses,

filing / Aug 6, 2026 / receipt

In connection with the proposed merger with Avere Therapeutics, we approved a restructuring plan intended to significantly reduce operating expenses and align our organization with the anticipated strategy of the combined company.

filing / Aug 6, 2026 / receipt

Subsequent to June 30, 2026, in connection with the anticipated Merger, the Company approved a restructuring plan intended to significantly reduce operating expenses and wind down certain legacy oncology development activities.

filing / Aug 6, 2026 / receipt

Asset impairment charges were $5.1 million for the three and six months ended June 30, 2026, reflecting the write-down of property and equipment, right-of-use assets and related improvements in connection with our restructuring initiatives.

filing / Aug 6, 2026 / receipt

The restructuring includes a substantial workforce reduction and related severance obligations. The Company currently estimates restructuring charges of approximately $2.4 million, consisting primarily of employee severance and related costs.

filing / Aug 6, 2026 / receipt

● the costs of outside consultants, including their fees, stock-based compensation and related travel expenses; ● the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; ● salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; and ● facility-related expenses,

filing / May 7, 2026 / receipt

to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on our technologies; risks related to our restructuring and reduction in force; and our dependence on key personnel.

filing / May 7, 2026 / receipt